FCCC LOGO Faculty Publications
Campbell Kerry S
Genetically modified human natural killer cell lines expressing Fc receptor for assessing efficacy of antibody against cancer or infection
. 2006 07/08/2005 :90 pp
PMID: AN 2006:333462   
Back to previous list
Abstract
The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD 16 (FcgRIII-A), or other Fcy or Fc receptors. The modified NK-92 cell can be further modified to concurrently express an assocd. accessory signaling protein, such as FceRI-g,TCR-z, or to concurrently express interleukin-2 (IL-2) or other cytokines. Addnl. methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells. [on SciFinder (R)]
Notes
CAN 144:348896 15-3 Immunochemistry Patent written in English. 20060302 881319-22-8P; 881319-23-9P; 881319-26-2P; 881319-28-4P (TCR (receptor) (Human z-subunit) Role: ARU (Analytical role, unclassified), BPN (Biosynthetic preparation), BSU (Biological study, unclassified), PRP (Properties), ANST (Analytical study), BIOL (Biological study), PREP (Preparation) (amino acid sequence; genetically modified human natural killer cell lines expressing Fc receptor for assessing efficacy of antibody against cancer or infection); 384441-61-6P (Genbank J04132); 389186-97-4P (Genbank M33195) Role: ARU (Analytical role, unclassified), BPN (Biosynthetic preparation), BSU (Biological study, unclassified), PRP (Properties), ANST (Analytical study), BIOL (Biological study), PREP (Preparation) (genetically modified human natural killer cell lines expressing Fc receptor for assessing efficacy of antibody against cancer or infection); 881319-24-0P; 881319-25-1P; 881319-27-3P Role: ARU (Analytical role, unclassified), BPN (Biosynthetic preparation), BSU (Biological study, unclassified), PRP (Properties), ANST (Analytical study), BIOL (Biological study), PREP (Preparation) (nucleotide sequence; genetically modified human natural killer cell lines expressing Fc receptor for assessing efficacy of antibody against cancer or infection) A2 US 2004-586581 20040710